Bloomberg News
@Bloomberg-News·2.8M subscribers·40.1K videos
Ozempic Slashes Risk of Death in Kidney Disease Study
Posted
May 24, 2024
Views
2,379
Likes
56
Comments
3
Engagement
2.48%
May 24, 2024
2,379
56
3
2.48%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
0:30Now PlayingNovo Nordisk A/S’s blockbuster diabetes drug Ozempic cut patients’ risk of dying in a kidney-disease study, the latest research pointing to the medicine’s usefulness in a constellation of disorders.
Patients with kidney disease caused by diabetes were one-fifth less likely to die of any cause during the study if they took Ozempic rather than a placebo, scientists said in the New England Journal of Medicine on Friday. Novo stopped the trial ahead of schedule last year after an early analysis showed how much the drug helped, sparking a $3.6 billion selloff in shares of kidney dialysis providers Fresenius Medical Care AG and DaVita Inc.
--------
Subscribe to our YouTube channel
Subscribe to Bloomberg Originals
Bloomberg Quicktake brings you global social video spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.
Connect with us on…
Breaking News on YouTube
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
